Evaluation of Potentially Common Adverse Events Associated With the First and Second Doses of Measles-Mumps-Rubella Vaccine

BACKGROUND/OBJECTIVES. In 1989, the American Academy of Pediatrics and the Advisory Committee on Immunization Practices recommended that school children receive 2 doses of measles-mumps-rubella vaccine. With measles and rubella eliminated from the United States, measles-mumps-rubella vaccine adverse events have come under scrutiny, but no study has compared the reactogenicity of the first (measles-mumps-rubella vaccine dose 1) and second (measles-mumps-rubella vaccine dose 2) doses at the most common ages of administration in the United States. METHODS. From a health maintenance organization, 3 groups of children were recruited: (1) toddlers aged 12 to 24 months receiving measles-mumps-rubella vaccine dose 1; (2) kindergartners aged 4 to 6 years receiving measles-mumps-rubella vaccine dose 2; and (3) middle schoolers aged 10 to 12 years receiving measles-mumps-rubella vaccine dose 2. From 2 weeks before measles-mumps-rubella vaccine administration until 4 weeks afterward, families recorded in diaries the occurrence of potentially common symptoms. Postvaccination symptom rates were compared with the prevaccination baseline, with significance assessed by testing incidence rate ratios estimated by Poisson regression. RESULTS. Of 2173 children enrolled, 373 (17%) were lost to attrition, producing a study population of 1800. Compared with the prevaccination baseline, rates of fever, diarrhea, and rash were significantly elevated postvaccination among 535 toddlers receiving measles-mumps-rubella vaccine dose 1. An estimated net 95 (18%) experienced measles-mumps-rubella vaccine-associated events (median onset 5–10 days postvaccination, duration 2–5 days), with high fever (temperature ≥39.5°C) occurring in 33 (6%). None required medical attention. For 633 kindergartners and 632 middle schoolers, symptom rates were not significantly elevated after measles-mumps-rubella vaccine dose 2 compared with baseline. CONCLUSIONS. Vaccination-associated adverse events occur in ∼1 of every 6 toddlers receiving measles-mumps-rubella vaccine dose 1, with high fever occurring in 1 of 20. Adverse events are infrequent for measles-mumps-rubella vaccine dose 2 administered to school-aged children.

[1]  J. Olsen,et al.  MMR vaccination and febrile seizures: evaluation of susceptible subgroups and long-term prognosis. , 2004, JAMA.

[2]  H. Izurieta,et al.  Measles eradication in the Americas: progress to date. , 2004, The Journal of infectious diseases.

[3]  A. Hinman,et al.  Summary and conclusions: measles elimination meeting, 16-17 March 2000. , 2004, The Journal of infectious diseases.

[4]  Ron Dagan,et al.  Fever as an adverse event following immunization: case definition and guidelines of data collection, analysis, and presentation. , 2004, Vaccine.

[5]  N. Stollenwerk,et al.  Measles Outbreaks in a Population with Declining Vaccine Uptake , 2003, Science.

[6]  Robert T. Chen,et al.  The Brighton Collaboration: enhancing comparability of vaccine safety data , 2003, Pharmacoepidemiology and Drug Safety.

[7]  H Jick,et al.  Mumps, measles, and rubella vaccine and the incidence of autism recorded by general practitioners: a time trend analysis , 2001, BMJ : British Medical Journal.

[8]  O. Heinonen,et al.  Day-to-Day Reactogenicity and the Healthy Vaccinee Effect of Measles-Mumps-Rubella Vaccination , 2000, Pediatrics.

[9]  Gwendolyn Halford,et al.  County and City Data Book , 1999 .

[10]  E. Miller,et al.  Impact of anti-vaccine movements on pertussis control: the untold story , 1998, The Lancet.

[11]  B. Schwartz,et al.  Age for Routine Administration of the Second Dose of Measles–Mumps–Rubella Vaccine , 1998, Pediatrics.

[12]  R. Davis,et al.  MMR2 immunization at 4 to 5 years and 10 to 12 years of age: a comparison of adverse clinical events after immunization in the Vaccine Safety Datalink project. The Vaccine Safety Datalink Team. , 1997, Pediatrics.

[13]  John W. Glasser,et al.  Vaccine Safety Datalink project: a new tool for improving vaccine safety monitoring in the United States. The Vaccine Safety Datalink Team. , 1997, Pediatrics.

[14]  J. Moses,et al.  Adverse events following measles-mumps-rubella and measles vaccinations in college students. , 1991, Vaccine.

[15]  O. Heinonen,et al.  FREQUENCY OF TRUE ADVERSE REACTIONS TO MEASLES-MUMPS-RUBELLA VACCINE A Double-blind Placebo-controlled Trial in Twins , 1986, The Lancet.

[16]  S. Kimmel,et al.  Enhancement of medication recall using medication pictures and lists in telephone interviews , 2003, Pharmacoepidemiology and drug safety.

[17]  L. Gothefors,et al.  Immunogenicity and reactogenicity of a new measles, mumps and rubella vaccine when administered as a second dose at 12 y of age. , 2001, Scandinavian journal of infectious diseases.

[18]  J. P. Davis,et al.  Measles, mumps, and rubella--vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). , 1998, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[19]  T. Tulchinsky,et al.  Measles control in developing and developed countries: the case for a two-dose policy. , 1993, Bulletin of the World Health Organization.

[20]  Rubella prevention. Recommendations of the Immunization Practices Advisory Committee (ACIP). , 1990, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[21]  J. L. Montagne,et al.  Measles: Reassessment of the current immunization policy , 1989 .